Simplified Molecular International Prognostic Index as an eligibility criterion for clinical trials: Analysis of the Turkish Lymphoma Study Group's large B-cell lymphoma cohort.

ABSTRACT: Comparative first-line trials in large B-cell lymphoma (LBCL) have mostly failed over the last decade. Failures were commonly attributed to overestimation of the progression risk for the control arms, bringing the precision of the international prognostic index (IPI) into scrutiny. Simplified molecular IPI (smIPI), introduced at American Society of Hematology 2023, was developed to address the shortcomings of IPI. This study investigated smIPI and its potential implications as trial eligibility criteria among a multicentre LBCL cohort of 1439 patients. Patients diagnosed between 2012 and 2024 were included. Data were collected from institutional archives. The primary end-point was risk stratification for progression-free survival (PFS). Kaplan-Meier and Cox regression methods were used for

SUBMITTER: Yılmaz U 

PROVIDER: S-EPMC12819096 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature